BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Psoriasis readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Psoriasis\, from Clin
 icalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07672561-1865@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20261130
DTEND;VALUE=DATE:20261201
SUMMARY:WD-890: Phase 3 readout est. (NCT07672561)
DESCRIPTION:WD-890\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomize
 d\, Double-Blind\, Placebo-Controlled Phase Ⅲ Study to Evaluate the Effi
 cacy and Safety of WD-890 Tablets for the Treatment of Moderate to Severe 
 Plaque Psoriasis\nEstimated primary completion: 30 November 2026. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/wd-890#upcoming-events\nRegis
 try record: https://clinicaltrials.gov/study/NCT07672561
URL:https://assetmemo.bio/drug/wd-890#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07158268-64@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20261220
DTEND;VALUE=DATE:20261221
SUMMARY:HSK47388: Phase 2 readout est. (NCT07158268)
DESCRIPTION:HSK47388\, phase 2\, Psoriasis.\nStudy: A Phase 2 Study of HSK4
 7388 Tablets to Evaluate the Efficacy and Safety in Patients With Moderate
 -to-Severe Plaque Psoriasis\nEstimated primary completion: 20 December 202
 6. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/hsk47388#upcoming-
 events\nRegistry record: https://clinicaltrials.gov/study/NCT07158268
URL:https://assetmemo.bio/drug/hsk47388#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07719530-31@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07719530)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: Phase II Clinical Trial
  of SHR-1139 Injection in Patients With Psoriasis\nEstimated primary compl
 etion: 31 December 2026. This is a ClinicalTrials.gov estimate\, not a con
 firmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/d
 rug/shr-1139#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07719530
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05981118-1783@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:Tapinarof: Phase 2/3 readout est. (NCT05981118)
DESCRIPTION:Tapinarof\, phase 2/3\, Psoriasis.\nStudy: Comparison of Post-I
 nflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant
 )\nEstimated primary completion: January 2027. This is a ClinicalTrials.go
 v estimate\, not a confirmed readout date\, and it can move.\nDrug page: h
 ttps://assetmemo.bio/drug/tapinarof#upcoming-events\nRegistry record: http
 s://clinicaltrials.gov/study/NCT05981118
URL:https://assetmemo.bio/drug/tapinarof#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07543224-1475@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270131
DTEND;VALUE=DATE:20270201
SUMMARY:RSS0393: Phase 3 readout est. (NCT07543224)
DESCRIPTION:RSS0393\, phase 3\, Psoriasis.\nStudy: A Multicenter\, Randomiz
 ed\, Double-Blind\, Placebo-Controlled Phase III Clinical Study to Evaluat
 e the Efficacy and Safety of RSS0393 Ointment in Adult Patients With Plaqu
 e Psoriasis.\nEstimated primary completion: January 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/rss0393#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT07543224
URL:https://assetmemo.bio/drug/rss0393#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07765628-1807@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:HS-20118: Phase 2 readout est. (NCT07765628)
DESCRIPTION:HS-20118\, phase 2\, Psoriasis.\nStudy: A Phase 2 Study of HS-2
 0118 to Evaluate the Efficacy and Safety in Participant With Moderate-to-S
 evere Plaque Psoriasis\nEstimated primary completion: 28 February 2027. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/hs-20118#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT07765628
URL:https://assetmemo.bio/drug/hs-20118#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07623486-1385@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HSK44459: Phase 1/2 readout est. (NCT07623486)
DESCRIPTION:HSK44459\, phase 1/2\, Psoriasis.\nStudy: Trial of HSK44459 Cre
 am for the Management Plaque Psoriasis\nEstimated primary completion: Marc
 h 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout da
 te\, and it can move.\nDrug page: https://assetmemo.bio/drug/hsk44459#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07623486
URL:https://assetmemo.bio/drug/hsk44459#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07879885-1951@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270301
DTEND;VALUE=DATE:20270302
SUMMARY:HS-20137: Phase 2 readout est. (NCT07879885)
DESCRIPTION:HS-20137\, phase 2\, Psoriasis.\nStudy: An Open-label Study of 
 HS-20137 in Participants With Moderate-to-Severe Plaque Psoriasis\nEstimat
 ed primary completion: 1 March 2027. This is a ClinicalTrials.gov estimate
 \, not a confirmed readout date\, and it can move.\nDrug page: https://ass
 etmemo.bio/drug/hs-20137#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT07879885
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06506916-92@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270309
DTEND;VALUE=DATE:20270310
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06506916)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriatic Arthritis.\nStudy: 
 A Study to Evaluate the Effect of Bimekizumab on Gene Expression Biomarker
 s in Study Participants With Moderate to Severe Plaque Psoriasis\nEstimate
 d primary completion: 9 March 2027. This is a ClinicalTrials.gov estimate\
 , not a confirmed readout date\, and it can move.\nDrug page: https://asse
 tmemo.bio/drug/bimekizumab#upcoming-events\nRegistry record: https://clini
 caltrials.gov/study/NCT06506916
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06844799-1951@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270331
DTEND;VALUE=DATE:20270401
SUMMARY:HS-20137: Phase 3 readout est. (NCT06844799)
DESCRIPTION:HS-20137\, phase 3\, Psoriasis.\nStudy: A Study of HS-20137 in 
 Participants with Moderate-to-severe Plaque Psoriasis\nEstimated primary c
 ompletion: 31 March 2027. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/hs-20137#upcoming-events\nRegistry record: https://clinicaltrials.gov
 /study/NCT06844799
URL:https://assetmemo.bio/drug/hs-20137#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06943950-1927@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270428
DTEND;VALUE=DATE:20270429
SUMMARY:SYHX1901: Phase 3 readout est. (NCT06943950)
DESCRIPTION:SYHX1901\, phase 3\, Psoriasis.\nStudy: A Phase III Study of SY
 HX1901 Tablets in the Treatment of Moderate to Severe Plaque Psoriasis\nEs
 timated primary completion: 28 April 2027. This is a ClinicalTrials.gov es
 timate\, not a confirmed readout date\, and it can move.\nDrug page: https
 ://assetmemo.bio/drug/syhx1901#upcoming-events\nRegistry record: https://c
 linicaltrials.gov/study/NCT06943950
URL:https://assetmemo.bio/drug/syhx1901#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07752108-101@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270530
DTEND;VALUE=DATE:20270531
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07752108)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of Zasocitin
 ib in Adults With Non-pustular Palmoplantar Psoriasis\nEstimated primary c
 ompletion: 30 May 2027. This is a ClinicalTrials.gov estimate\, not a conf
 irmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dr
 ug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT07752108
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07758075-31@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SHR-1139: Phase 2 readout est. (NCT07758075)
DESCRIPTION:SHR-1139\, phase 2\, Psoriasis.\nStudy: A Phase II Clinical Stu
 dy to Evaluate the Efficacy and Safety of SHR-1139 Injection in Patients W
 ith Plaque Psoriasis\nEstimated primary completion: July 2027. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/shr-1139#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07758075
URL:https://assetmemo.bio/drug/shr-1139#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07326813-62@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270712
DTEND;VALUE=DATE:20270713
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07326813)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: A Clinical
  Study to Evaluate the Efficacy and Safety of D-2570 in the Treatment of M
 oderate to Severe Plaque Psoriasis\nEstimated primary completion: 12 July 
 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/nomelcitinib-d-
 2570#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NC
 T07326813
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07130604-62@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270728
DTEND;VALUE=DATE:20270729
SUMMARY:Nomelcitinib (D-2570): Phase 3 readout est. (NCT07130604)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 3\, Psoriasis.\nStudy: Evaluate t
 he Efficacy and Safety of D-2570 in Subjects With Moderate to Severe Plaqu
 e Psoriasis\nEstimated primary completion: 28 July 2027. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nR
 egistry record: https://clinicaltrials.gov/study/NCT07130604
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07489885-62@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270831
DTEND;VALUE=DATE:20270901
SUMMARY:Nomelcitinib (D-2570): Phase 2 readout est. (NCT07489885)
DESCRIPTION:Nomelcitinib (D-2570)\, phase 2\, Psoriasis.\nStudy: A Study to
  Evaluate D-2570 in Participants With Moderate to Severe Plaque Psoriasis\
 nEstimated primary completion: August 2027. This is a ClinicalTrials.gov e
 stimate\, not a confirmed readout date\, and it can move.\nDrug page: http
 s://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07489885
URL:https://assetmemo.bio/drug/nomelcitinib-d-2570#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07724366-52@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:TQH3906: Phase 3 readout est. (NCT07724366)
DESCRIPTION:TQH3906\, phase 3\, Psoriasis.\nStudy: A Clinical Trial of TQH3
 906 Capsules in Adult Patients With Moderate to Severe Plaque Psoriasis\nE
 stimated primary completion: September 2027. This is a ClinicalTrials.gov 
 estimate\, not a confirmed readout date\, and it can move.\nDrug page: htt
 ps://assetmemo.bio/drug/tqh3906#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT07724366
URL:https://assetmemo.bio/drug/tqh3906#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07129382-1857@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270918
DTEND;VALUE=DATE:20270919
SUMMARY:CS32582: Phase 1/2 readout est. (NCT07129382)
DESCRIPTION:CS32582\, phase 1/2\, Psoriasis.\nStudy: A Study to Evaluate th
 e Efficacy and Safety of CS32582 in Participants With Moderate to Severe P
 laque Psoriasis\nEstimated primary completion: 18 September 2027. This is 
 a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can 
 move.\nDrug page: https://assetmemo.bio/drug/cs32582#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07129382
URL:https://assetmemo.bio/drug/cs32582#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03886246-42@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Spevigo (spesolimab): Phase 2 readout est. (NCT03886246)
DESCRIPTION:Spevigo (spesolimab)\, phase 2\, Psoriasis.\nStudy: Effisayil
 ™ ON: A Study to Test Long-term Treatment With Spesolimab in People With
  Generalized Pustular Psoriasis Who Took Part in a Previous Study\nEstimat
 ed primary completion: 30 September 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/spesolimab#upcoming-events\nRegistry record: https://
 clinicaltrials.gov/study/NCT03886246
URL:https://assetmemo.bio/drug/spesolimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07474792-1909@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20271031
DTEND;VALUE=DATE:20271101
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07474792)
DESCRIPTION:ORKA-002\, phase 2\, Psoriasis.\nStudy: Dose Ranging Study of O
 RKA-002 in Patients With Moderate-to-Severe Plaque Psoriasis\nEstimated pr
 imary completion: October 2027. This is a ClinicalTrials.gov estimate\, no
 t a confirmed readout date\, and it can move.\nDrug page: https://assetmem
 o.bio/drug/orka-002#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07474792
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06643260-1801@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Piclidenoson: Phase 3 readout est. (NCT06643260)
DESCRIPTION:Piclidenoson\, phase 3\, Psoriasis.\nStudy: A Phase 3 Study in 
 Moderate-to-Severe Plaque Psoriasis With Piclidenoson to Study Safety and 
 Efficacy\nEstimated primary completion: December 2027. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/piclidenoson#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT06643260
URL:https://assetmemo.bio/drug/piclidenoson#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05739435-1803@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20271201
DTEND;VALUE=DATE:20271202
SUMMARY:Envudeucitinib: Phase 2 readout est. (NCT05739435)
DESCRIPTION:Envudeucitinib\, phase 2\, Psoriasis.\nStudy: Open-Label Extens
 ion Study to Evaluate the Long Term Safety and Efficacy of ESK-001 in Plaq
 ue Psoriasis\nEstimated primary completion: 1 December 2027. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/envudeucitinib#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT05739435
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07511647-1920@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20271230
DTEND;VALUE=DATE:20271231
SUMMARY:QL2106: Phase 3 readout est. (NCT07511647)
DESCRIPTION:QL2106\, phase 3\, Psoriasis.\nStudy: A Phase 3 Clinical Study 
 of QL2106 Injection\nEstimated primary completion: 30 December 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/ql2106#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT07511647
URL:https://assetmemo.bio/drug/ql2106#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06620692-1373@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:GM-XANTHO: Phase 2 readout est. (NCT06620692)
DESCRIPTION:GM-XANTHO\, phase 2\, Psoriasis.\nStudy: A Study to Investigate
  the Efficacy and Safety Profile of GM-XANTHO [GM-XAN003] in Patients With
  Psoriasis\nEstimated primary completion: 31 December 2027. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/gm-xantho#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06620692
URL:https://assetmemo.bio/drug/gm-xantho#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07432854-1339@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20280229
DTEND;VALUE=DATE:20280301
SUMMARY:CMS-D001: Phase 2/3 readout est. (NCT07432854)
DESCRIPTION:CMS-D001\, phase 2/3\, Psoriasis.\nStudy: A Clinical Study Eval
 uating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adu
 lt Patients With Moderate to Severe Plaque-type Psoriasis\nEstimated prima
 ry completion: 29 February 2028. This is a ClinicalTrials.gov estimate\, n
 ot a confirmed readout date\, and it can move.\nDrug page: https://assetme
 mo.bio/drug/cms-d001#upcoming-events\nRegistry record: https://clinicaltri
 als.gov/study/NCT07432854
URL:https://assetmemo.bio/drug/cms-d001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04862286-3@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Skyrizi (risankizumab): Phase 3 readout est. (NCT04862286)
DESCRIPTION:Skyrizi (risankizumab)\, phase 3\, Psoriasis.\nStudy: Study to 
 Evaluate Adverse Events and Change in Disease Activity in Participants Bet
 ween 6 and 17 Years With Moderate to Severe Plaque Psoriasis Treated With 
 Subcutaneous (SC) Injection of Risankizumab Who Have Completed Participati
 on in Study M19-977\nEstimated primary completion: April 2028. This is a C
 linicalTrials.gov estimate\, not a confirmed readout date\, and it can mov
 e.\nDrug page: https://assetmemo.bio/drug/risankizumab#upcoming-events\nRe
 gistry record: https://clinicaltrials.gov/study/NCT04862286
URL:https://assetmemo.bio/drug/risankizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06742333-92@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20280722
DTEND;VALUE=DATE:20280723
SUMMARY:Bimzelx (bimekizumab): Phase 2 readout est. (NCT06742333)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 2\, Psoriasis.\nStudy: Early Inte
 rvention in Plaque Psoriasis: is Bimekizumab Able to Delay Chronic Inflamm
 ation?\nEstimated primary completion: 22 July 2028. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT06742333
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07362017-1919@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Ponesimod: Phase 3 readout est. (NCT07362017)
DESCRIPTION:Ponesimod\, phase 3\, Psoriasis.\nStudy: Open Label Study to In
 vestigate the Safety and Efficacy of Ponesimod in Moderate-to-Severe Chron
 ic Plaque Psoriasis\nEstimated primary completion: August 2028. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/ponesimod#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT07362017
URL:https://assetmemo.bio/drug/ponesimod#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06425549-92@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20280821
DTEND;VALUE=DATE:20280822
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT06425549)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriasis.\nStudy: A Study to
  Evaluate the Efficacy and Safety of Bimekizumab Compared to Ustekinumab i
 n Children and Adolescents From 6 Years to Less Than 18 Years of Age With 
 Moderate to Severe Plaque Psoriasis\nEstimated primary completion: 21 Augu
 st 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/bimekizumab#
 upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT0642
 5549
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06846541-1803@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20281130
DTEND;VALUE=DATE:20281201
SUMMARY:Envudeucitinib: Phase 3 readout est. (NCT06846541)
DESCRIPTION:Envudeucitinib\, phase 3\, Psoriasis.\nStudy: Long-term Safety 
 and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis\nEstimated 
 primary completion: November 2028. This is a ClinicalTrials.gov estimate\,
  not a confirmed readout date\, and it can move.\nDrug page: https://asset
 memo.bio/drug/envudeucitinib#upcoming-events\nRegistry record: https://cli
 nicaltrials.gov/study/NCT06846541
URL:https://assetmemo.bio/drug/envudeucitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04772079-100@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20290101
DTEND;VALUE=DATE:20290102
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT04772079)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Drug Levels\, Efficacy and Safety of Deucravacitinib in 
 Children and Adolescent Participants With Moderate to Severe Plaque Psoria
 sis\nEstimated primary completion: 1 January 2029. This is a ClinicalTrial
 s.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pag
 e: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT04772079
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07933783-1909@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20290701
DTEND;VALUE=DATE:20290702
SUMMARY:ORKA-002: Phase 2 readout est. (NCT07933783)
DESCRIPTION:ORKA-002\, phase 2\, Psoriasis.\nStudy: An Open-label Study Wit
 h Maintenance Dosing of ORKA-002 in Participants With Moderate-to-Severe P
 laque Psoriasis\nEstimated primary completion: 1 July 2029. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/orka-002#upcoming-events\nRegistry 
 record: https://clinicaltrials.gov/study/NCT07933783
URL:https://assetmemo.bio/drug/orka-002#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06550076-101@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20290805
DTEND;VALUE=DATE:20290806
SUMMARY:zasocitinib: Phase 3 readout est. (NCT06550076)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Study of TAK-279 i
 n Participants With Moderate-to-Severe Plaque Psoriasis\nEstimated primary
  completion: 5 August 2029. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltrial
 s.gov/study/NCT06550076
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06979453-100@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20291012
DTEND;VALUE=DATE:20291013
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT06979453)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: A Stud
 y to Evaluate the Efficacy\, Safety\, and Drug Levels of Deucravacitinib (
 BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psor
 iasis\nEstimated primary completion: 12 October 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/deucravacitinib#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT06979453
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07836283-92@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20300415
DTEND;VALUE=DATE:20300416
SUMMARY:Bimzelx (bimekizumab): Phase 3 readout est. (NCT07836283)
DESCRIPTION:Bimzelx (bimekizumab)\, phase 3\, Psoriasis.\nStudy: Evaluation
  of the Efficacy and Safety of Bimekizumab (BZK) or Adalimumab (ADA) in th
 e Treatment of Anterior Chest Wall Pain Associated With Active Axial Spond
 yloarthritis Refractory to NSAIDs With Hypothesis of Superiority of Bimeki
 zumab\nEstimated primary completion: 15 April 2030. This is a ClinicalTria
 ls.gov estimate\, not a confirmed readout date\, and it can move.\nDrug pa
 ge: https://assetmemo.bio/drug/bimekizumab#upcoming-events\nRegistry recor
 d: https://clinicaltrials.gov/study/NCT07836283
URL:https://assetmemo.bio/drug/bimekizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07449702-1812@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20300531
DTEND;VALUE=DATE:20300601
SUMMARY:Avrukibart: Phase 2 readout est. (NCT07449702)
DESCRIPTION:Avrukibart\, phase 2\, Psoriasis.\nStudy: An Open-Label Extensi
 on Study of ORKA-001 in Participants With Plaque Psoriasis\nEstimated prim
 ary completion: May 2030. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/avrukibart#upcoming-events\nRegistry record: https://clinicaltrials.g
 ov/study/NCT07449702
URL:https://assetmemo.bio/drug/avrukibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07791199-100@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20301031
DTEND;VALUE=DATE:20301101
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07791199)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriatic Arthritis.\nStu
 dy: Continued Access to Deucravacitinib for Adult SLE/SjD and Pediatric Ps
 O/PsA Study Completers\nEstimated primary completion: 31 October 2030. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcoming
 -events\nRegistry record: https://clinicaltrials.gov/study/NCT07791199
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07116967-100@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20310116
DTEND;VALUE=DATE:20310117
SUMMARY:Sotyktu (deucravacitinib): Phase 3 readout est. (NCT07116967)
DESCRIPTION:Sotyktu (deucravacitinib)\, phase 3\, Psoriasis.\nStudy: Long-T
 erm Safety Study of Deucravacitinib Versus Ustekinumab in Participants Wit
 h Psoriasis (PRAGMATYK)\nEstimated primary completion: 16 January 2031. Th
 is is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and i
 t can move.\nDrug page: https://assetmemo.bio/drug/deucravacitinib#upcomin
 g-events\nRegistry record: https://clinicaltrials.gov/study/NCT07116967
URL:https://assetmemo.bio/drug/deucravacitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07250802-101@assetmemo.bio
DTSTAMP:20261121T004502Z
DTSTART;VALUE=DATE:20340703
DTEND;VALUE=DATE:20340704
SUMMARY:zasocitinib: Phase 3 readout est. (NCT07250802)
DESCRIPTION:zasocitinib\, phase 3\, Psoriasis.\nStudy: A Long-Term Study of
  Zasocitinib in Children and Teenagers With Plaque Psoriasis\nEstimated pr
 imary completion: 3 July 2034. This is a ClinicalTrials.gov estimate\, not
  a confirmed readout date\, and it can move.\nDrug page: https://assetmemo
 .bio/drug/zasocitinib#upcoming-events\nRegistry record: https://clinicaltr
 ials.gov/study/NCT07250802
URL:https://assetmemo.bio/drug/zasocitinib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
